GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (XPAR:NANO) » Definitions » Total Long-Term Liabilities

Nanobiotix (XPAR:NANO) Total Long-Term Liabilities : €45.87 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Nanobiotix Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Nanobiotix's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was €45.87 Mil.

Nanobiotix Total Long-Term Liabilities Historical Data

The historical data trend for Nanobiotix's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanobiotix Total Long-Term Liabilities Chart

Nanobiotix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.77 44.52 38.13 48.88 45.87

Nanobiotix Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.13 36.25 48.88 44.34 45.87

Nanobiotix Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Nanobiotix Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Nanobiotix's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanobiotix (XPAR:NANO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (XPAR:NANO) » Definitions » Total Long-Term Liabilities
Comparable Companies
XPAR:DBV XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:MEDCL XPAR:GNFT XPAR:TNG XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
NBTX:USA 5NR:Germany
Address
60 Rue de Wattignies, Paris, FRA, 75012
Website
https://www.nanobiotix.com
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Nanobiotix (XPAR:NANO) Headlines

No Headlines